Cosmos Health Resumes Share Buybacks With $3.85 Million Left Under Authorization
Key Facts
Cosmos Health said on November 19 it was resuming open-market share repurchases, with about $3.85 million remaining under a program of up to $5 million. The company said the remaining amount was calculated as of September 30, while the program remains in effect through year-end unless the company renews the authorization at its discretion. The announcement follows a pause in purchases and redirects the existing authorization toward new buybacks. According to the company, it had bought 255,600 shares after the reverse split by the announcement date, equivalent to 5,112,000 shares before the split, for about $1.15 million. The company linked the program to management's belief that the stock is undervalued, without describing it as a reflection of confidence in its current market value.
The board authorized the program on June 26, setting a $5 million cap and an expiration date of December 31. The authorization gives the company the ability to repurchase shares, but does not require it to spend the full allocated amount; about $3.85 million remained available, according to the November 19 announcement. During the second quarter, the company repurchased 2,650,000 shares for about $513,000. These earlier purchases indicate that the authorization was executed in stages, with spending below the overall cap. The resumption of purchases now coincides with a separate commitment by the company's management and board to hold their shares.
The company said its executive officers and directors agreed not to sell or otherwise dispose of the common shares they own for 12 months. This pledge differs from the buyback program: it concerns shares held by insiders, while the program allows the company to buy shares in the market. The company thus combined, in its announcement, a move to purchase shares with a commitment by its officers to retain their holdings. It said the timing and volume of purchases would depend on market conditions and other factors. The program may also be suspended or discontinued at any time, leaving execution of the remaining amount uncertain.
The program's resumption followed a 1-for-20 reverse stock split approved by the board on October 27. The board kept the number of authorized common shares at 1,500,000,000 alongside approval of the split. Counting purchases after the split means that 255,600 shares equal 5,112,000 shares on the pre-adjustment share count. The split affects the number of shares and the per-share price and does not, by itself, establish a stated purpose of enhancing shareholder rights or a change in the company's operating performance. COSM shares closed at $2.85 on November 17 and $2.95 on November 18, according to EL7 data.
In operating results for the same period of the year, the company reported revenue of $53.59 million for the nine months ended September 30, up 17.6% from $45.57 million in the comparable period of 2025. Third-quarter revenue was $16.68 million, compared with $17.11 million in the third quarter of the prior year. On a quarterly basis, gross margin rose to 12.6% in the third quarter from 7.96% in the second quarter, an increase of 465 basis points. Adjusted EBITDA loss also narrowed by about 18% to $0.93 million from $1.13 million in the prior quarter. These figures place the buyback announcement in the context of the financial results reported by the company, without making the purchases a substitute for evaluating operating performance.
Chief Executive Greg Siokas said the company had reduced total debt by about one-third since January, cut total liabilities by 18%, and increased shareholders' equity by more than 20%. The company added that it entered the fourth quarter with more than 12,500 active U.S. subscriptions and monthly subscription value of $1.83 million. It also said its contract manufacturing pipeline exceeded 32.7 million units as the quarter began. These indicators provide background to what the company described as progress in its business, while buyback execution remains subject to market conditions and the possibility that the authorization could be suspended. The program expires on December 31 unless the company decides to renew it.